Across TCGA pan-cancer cohorts, STMN3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STMN3 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STMN3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STMN3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where STMN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.190	0.679	.004	14	view →
LUAD	DFS	Tertile	II,III,IV	0.624	0.189	.024	6	view →
GBM	DFS	Quartile	All	0.896	0.692	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: STMN3 tumor-vs-normal RNA expression · all STMN3 data types